Treatment with scL-RB94 induced immunogenic changes of NSCLC by triggering immunogenic cell death (ICD), increasing type I interferon responses, and increasing expression of immune recognition molecules (e.g., ULBP2, MICA, and MICB for NK cells) and antigen processing and presentation machinery including peptide loading molecules (TAP1/2) and the antigen presentation molecule (HLA-ABC). Here, MICB is linked to non-small cell lung carcinoma.